Home › Compare › TGBMF vs ABBV
TGBMF yields 3.50% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, TGBMF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TGBMF + ABBV for your $10,000?
Taiwan Cement Corporation manufactures and markets cement, cement-related products, and ready mix concrete in Taiwan. It operates through Cement, Chemical Engineering, Electricity, and Other segments. The company also exports cement and cement clinkers. In addition, the company generates thermal and renewable energy; processes and sells refractory, chemical, and rubber raw materials, and batteries; sells limestone; and offers property leasing and energy technology, information software design, afforestation, industrial port management, marine transportation, engineering, construction and lease, waste collection and treatment, business consulting, port facility, software product and equipment maintenance, logistics and transportation, and dangerous waste treatment services. Further, it is involved in the sand and gravel filtering and sale; import and export trading; warehousing, and transportation; mining excavation activities; and manufacture and sale of slag powder. Taiwan Cement Corporation was incorporated in 1946 and is headquartered in Taipei, Taiwan.
Full TGBMF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.